Payment overview · 2025
General Payments
$4,347.00
223 reported records · 28 companies
Healthcare provider profile · identity verified
Matthew J Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · WATERLOO, IA · NPI 1609876507
Verified facts
What the public records show
CMS Open Payments records show Matthew J Smith, MD received $4,347.00 in general payments during 2025 across 223 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $579.19 | 13.3% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $535.62 | 12.3% | 23 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $518.59 | 11.9% | 31 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $323.79 | 7.5% | 25 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $296.89 | 6.8% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $294.93 | 6.8% | 20 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $262.09 | 6.0% | 9 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $192.06 | 4.4% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $175.65 | 4.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.44 | 4.0% | 8 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $151.38 | 3.5% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $123.56 | 2.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $122.14 | 2.8% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $118.64 | 2.7% | 6 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $103.12 | 2.4% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $61.60 | 1.4% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $51.44 | 1.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $41.45 | 0.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.37 | 0.8% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.95 | 0.7% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.76 | 0.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $21.27 | 0.5% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.65 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.83 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.00 | 0.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.92 | 0.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.90 | 0.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.77 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,347.00 | 223 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $454.57 | 28 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $323.79 | 25 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $305.00 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $303.68 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $299.70 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $296.89 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $295.01 | 23 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $272.08 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $262.09 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $254.85 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $219.97 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $201.20 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $201.20 | 9 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $192.06 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $175.65 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $151.38 | 15 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $145.28 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $145.28 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $144.48 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $123.56 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $103.12 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.63 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $86.81 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $72.23 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.80 | 3 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $51.44 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $41.45 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $31.95 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.42 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 178 |
| Pantoprazole Sodium | Pantoprazole Sodium | 461 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 131 |
| Simvastatin | Simvastatin | 341 | 105 |
| Lisinopril | Lisinopril | 312 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 97 |
| Meloxicam | Meloxicam | 310 | 88 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 306 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 71 |
| Omeprazole | Omeprazole | 232 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 194 | 65 |
| Metformin Hcl | Metformin Hcl | 189 | 56 |
| Prednisone | Prednisone | 189 | 142 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 51 |
| Furosemide | Furosemide | 158 | 55 |
| Losartan Potassium | Losartan Potassium | 150 | 48 |
| Allopurinol | Allopurinol | 146 | 46 |
| Azithromycin | Azithromycin | 137 | 108 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 47 |
| Metformin Hcl Er | Metformin Hcl | 132 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 45 |
| Glimepiride | Glimepiride | 110 | 37 |
| Ibuprofen | Ibuprofen | 109 | 42 |
| Alendronate Sodium | Alendronate Sodium | 107 | 39 |
| Potassium Chloride | Potassium Chloride | 105 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 49 |
| Montelukast Sodium | Montelukast Sodium | 98 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 26 |
| Eliquis | Apixaban | 84 | 23 |
| Gabapentin | Gabapentin | 84 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 31 |
| Carvedilol | Carvedilol | 81 | 24 |
| Tramadol Hcl | Tramadol Hcl | 80 | 28 |
| Atenolol | Atenolol | 72 | 23 |
| Levofloxacin | Levofloxacin | 72 | 63 |
| Famotidine | Famotidine | 67 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 19 |
| Finasteride | Finasteride | 62 | 20 |
| Bupropion Xl | Bupropion Hcl | 61 | 22 |
| Gemfibrozil | Gemfibrozil | 60 | 18 |
| Alprazolam | Alprazolam | 57 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 19 |
| Fenofibrate | Fenofibrate | 49 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 16 |
| Warfarin Sodium | Warfarin Sodium | 49 | 15 |
| Jardiance | Empagliflozin | 48 | 15 |
| Trazodone Hcl | Trazodone Hcl | 48 | 14 |
| Methylprednisolone | Methylprednisolone | 47 | 42 |
| Clonazepam | Clonazepam | 46 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 27 |
| Lovastatin | Lovastatin | 42 | 13 |
| Temazepam | Temazepam | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Sertraline Hcl | Sertraline Hcl | 39 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 37 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 24 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | 14 |
| Nitroglycerin | Nitroglycerin | 29 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 24 |
| Ozempic | Semaglutide | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 11 |
| Estradiol | Estradiol | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | 12 |
| Colchicine | Colchicine | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Naproxen | Naproxen | 22 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 11 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | 15 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 12 |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Levoxyl | Levothyroxine Sodium | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,347.00 · 223 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIGARD, ELIQUIS, ERLEADA, FARXIGA, IBSRELA, JARDIANCE, JOURNAVX, Jornay PM, KISUNLA, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, ORGOVYX, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TERIPARATIDE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Veozah, WATCHMAN Access System, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error